Bladder Cancer Study Decision Tree

Explore Bladder Cancer Studies

NMIBC – Low Grade

IR-NMIBC

TYRA 300-202

• A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

ABLE 32

• A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Subjects with Intermediate Risk Non-Muscle Invasive Bladder Cancer

NMIBC – High Grade CIS BCG Naïve

Reoccurrence of NMIBC – High Grade After 1 Induction of BCG

Moonrise 3

• TAR-210 Versus Intravesical Chemotherapy in Recurrent High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) with Susceptible FGFR Alterations

Reoccurrence of NMIBC – High Grade Ta/T1 after adequate BCG

Moonrise 3

• TAR-210 Versus Intravesical Chemotherapy in Recurrent High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) with Susceptible FGFR Alterations

Core-008 Cohort B

• A Phase 2, Multi-Cohort, Open-Label Study of Creostimogene Grenadenorepvec in High-Risk NMIBC

Reoccurrence of NMIBC High Grade CIS +/- Papillary Tumors after adequate BCG

ABLE 22

• A phase 2, randomized, multi-centre, open-label trial to evaluate the safety and efficacy of intravesical nadofaragene firadenovec alone or in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with high-grade Bacillus Calmette-Guerin unresponsive non-muscle invasive bladder cancer